본문으로 가기

학회지 검색

  • Journal of Multiple Sclerosis and Neuroimmunology 11(1):1-13, 2020
  • COVID-19 and Neuroimmunological Disorders
  • Seok-Jin Choi, MD, Seol-Hee Baek, MDa , Jiwon Yang, MDb , So-Young Huh, MDc , Kee Hong Park, MDd , Sang Beom Kim, MDe , Ko Woon Kim, MDf , Su-Yeon Park, MDg , Sung-Yeon Sohn, MDh , Jung-Hwan Oh, MDi , Je-Young Shin, MDj , Jee-Eun Kim, MDk , Suk-Won Ahn, MD, PhDl
  • Department of Neurology, Inha University School of Medicine, Incheon, Korea Department of Neurology, Korea University Anam Hospital, Seoul, Koreaa Department of Neurology, Gachon University Gil Medical Center, Incheon, Koreab Department of Neurology, Kosin University College of Medicine, Busan, Koreac Department of Neurology, Chungnam National University Sejong Hospital, Sejong, Koread Department of Neurology, Kyung Hee University Hospital at Gangdong, Seoul, Koreae Department of Neurology, Jeonbuk National University Hospital, Jeonbuk National University School of Medicine, Jeonju, Koreaf Department of Neurology, Korea Cancer Center Hospital, Seoul, Koreag Department of Neurology, Ajou University Hospital, Suwon, Koreah Department of Neurology, Jeju National University Hospital, Jeju, Koreai Department of Neurology, Seoul National University Hospital, Seoul, Koreaj Department of Neurology, College of Medicine, Ewha Womans University, Seoul, Koreak Department of Neurology, Chung-Ang University Hospital, Seoul, Koreal
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19) emerged in December 2019. Unfortunately, the World Health Organization declared COVID-19 a pandemic on March 2020. The pulmonary manifestations of COVID-19 have been well-described, and neurological manifestations including headache, anosmia, altered consciousness, stroke, and post-infectious autoimmunity, are being increasingly recognized. Furthermore, the COVID-19 pandemic is concerning for patients with neuroimmunological disorders who are receiving immunotherapy. It is not known if immunosuppression increases the risk of SARS-CoV-2 infection or worsens infection severity. Although national and international medical societies have developed several guidelines and statements, there is no consensus on neurological immunotherapy in COVID-19 patients. In this Review, we aimed to summarize international recommendations or currently available published reports, and provide management approaches to neurological immunotherapy in the COVID-19 era.
Journal of Multiple Sclerosis and Neuroimmunology 11(1):1-13, 2020
  • keyword : COVID-19; SARS-CoV-2; Neurology; Immunology; Immunotherapy